Yarrow Bioscience
Logotype for Yarrow Bioscience Inc

Yarrow Bioscience (YARW) investor relations material

Yarrow Bioscience Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Yarrow Bioscience Inc
Q3 2026 earnings summary12 Nov, 2026

Executive summary

  • YB-101 is an anti-TSHR antibody for Graves’ disease (GD) and thyroid eye disease (TED); the DIRECTION-GD Phase 2a/2b trial is underway, with Phase 2a topline results expected in H2 2027.

  • FDA cleared the GD investigational new drug application in March 2026 and granted Fast Track designation on May 20, 2026.

  • The first patient has been dosed in the randomized, blinded, placebo-controlled Phase 2a trial; enrollment is ongoing.

Financial highlights

  • Q3 2026 R&D and G&A expenses were $5.3M and $5.5M; operating loss was $10.7M and net loss was $9.7M.

  • For 9M 2026, R&D and G&A expenses were $11.5M and $8.8M; operating loss was $20.3M and net loss was $19.0M.

  • Other income, primarily interest, was $1.0M in Q3 and $1.3M for 9M 2026; no comparative 2025 periods are presented.

Outlook and guidance

  • Cash at September 30, 2026 is expected to fund operations into 2030, including DIRECTION-GD and preparation for a planned TED study; the estimate depends on assumptions that may change.

  • DIRECTION-GD Phase 2a topline results are expected in H2 2027; the trial evaluates safety, PK, PD and efficacy through 24 weeks.

  • Phase 2b is expected to begin enrolling in H1 2028 as a dose-finding study of ~200 patients, with dose selection informed by Phase 2a data.

  • GenSci’s Phase 1 TED multiple-ascending-dose data are expected in H2 2027 and to inform global TED development plans.

  • R&D costs are expected to rise as YB-101 advances; G&A is expected to increase with headcount, public-company costs and IP activity.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Yarrow Bioscience earnings date

Logotype for Yarrow Bioscience Inc
Q4 202626 Feb, 2027
Yarrow Bioscience
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Yarrow Bioscience earnings date

Logotype for Yarrow Bioscience Inc
Q4 202626 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing proprietary therapeutics for the treatment of immuno-inflammatory conditions. The company's product pipeline includes VYN201, a locally administered pan-BET inhibitor designed to address diseases involving multiple inflammatory cell signaling pathways with minimal systemic exposure. Additionally, VYNE is working on VYN202, a BD2-selective oral small molecule, and FMX114, a combination gel in clinical trials for atopic dermatitis. The company is headquartered in Bridgewater, New Jersey, and its shares are listed on the NASDAQ.